US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Corgi IP Licensing & Royalties ETF

26.44

0.0000

Volume:1

Turnover:26

Market Cap:1.45M

PE:- -

High:26.44

Open:26.44

Low:26.44

Close:26.44

52wk High:27.92

52wk Low:25.36

Shares:55.00K

Float Shares:55.00K

Volume Ratio:0.03

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

ROE:-378.67%

ROA:-70.26%

PB:0.13

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Palatin Technologies Shares Resume Trading on NYSE American

Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering

THOMSON REUTERS

Palatin Technologies Reports Zero Product Revenue for Fiscal Year Ending June 30, 2025, Following Sale of Vyleesi Rights

Palatin Technologies and Boehringer Ingelheim Strengthen Collaboration with €5.5 Million Milestone Achievement in Retinal Disease Research

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PTNT"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTNT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTNT\",,,,,undefined,":{"symbol":"PTNT","market":"US","secType":"STK","nameCN":"Corgi IP Licensing & Royalties ETF","latestPrice":26.4449,"timestamp":1782244800000,"preClose":26.4449,"halted":0,"volume":1,"delay":0,"changeRate":0,"floatShares":55000,"shares":55000,"eps":0,"marketStatus":"Pre-Mkt","change":0,"latestTime":"06-24 07:25:03 EDT","open":26.4449,"high":26.4449,"low":26.4449,"amount":26,"amplitude":0,"askPrice":41.8,"askSize":100,"bidPrice":10.52,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1782307800000},"marketStatusCode":1,"adr":0,"listingDate":1778040000000,"exchange":"CBOE","adjPreClose":26.4449,"nav":26.75,"aum":1471250,"bidAskSpread":0,"volumeRatio":0.027777685185493825,"impliedVol":0.5825,"impliedVolPercentile":0.2778},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTNT\",,,,,undefined,":{"symbol":"PTNT","floatShares":55000,"roa":"-70.26%","roe":"-378.67%","lyrEps":0,"volumeRatio":0.027777685185493825,"shares":55000,"dividePrice":0,"high":26.4449,"amplitude":0,"preClose":26.4449,"low":26.4449,"week52Low":25.36,"pbRate":"0.13","psRate":"0.16","week52High":27.924,"institutionHeld":0.1111,"latestPrice":26.4449,"committee":0.333333,"eps":0,"divideRate":0,"volume":1,"delay":0,"ttmEps":0,"open":26.4449,"prevYearClose":25.59,"prevWeekClose":26.4449,"prevMonthClose":27.153,"prevQuarterClose":25.59,"fiveDayClose":26.4449,"twentyDayClose":25.4599},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTNT\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTNT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTNT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTNT\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2583585033","title":"Palatin Technologies Shares Resume Trading on NYSE American","url":"https://stock-news.laohu8.com/highlight/detail?id=2583585033","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583585033?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:51","pubTimestamp":1762984283,"startTime":"0","endTime":"0","summary":"Palatin Technologies Inc. announced that trading of its common shares has resumed on the NYSE American exchange under the symbol \"PTN\" as of November 12, 2025. The company's shares were previously halted or suspended, and trading has now recommenced following the closing of an upsized public offering.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palatin Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL2sSpxx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTNT","PTN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581608320","title":"Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2581608320","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581608320?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:30","pubTimestamp":1762432201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA3ND1J0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTN","PTNT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2569746747","title":"Palatin Technologies Reports Zero Product Revenue for Fiscal Year Ending June 30, 2025, Following Sale of Vyleesi Rights","url":"https://stock-news.laohu8.com/highlight/detail?id=2569746747","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569746747?lang=en_us&edition=fundamental","pubTime":"2025-09-24 05:00","pubTimestamp":1758661233,"startTime":"0","endTime":"0","summary":"Palatin Technologies Inc., a biopharmaceutical company, released its financial results for the fiscal year ending June 30, 2025. The company reported no product revenue for the fiscal year 2025, compared to $4.49 million in product revenue for the fiscal year 2024. This decrease in net revenue is attributed to the sale of Vyleesi's worldwide rights to Cosette during fiscal 2024. No cost of products sold was recognized for fiscal 2025, in contrast to $97,637 recorded for fiscal 2024. Regarding future operations, Palatin Technologies stated that its existing cash and cash equivalents are expected to fund currently anticipated operating expenses through the second half of calendar year 2025. The company indicated a need for additional funding to complete required clinical trials and, if successful, to submit necessary regulatory applications to the FDA. Uncertain economic conditions may impact the company's operations and financial condition, potentially affecting its ability to access ca","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL59qzTK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2569078976","title":"Palatin Technologies and Boehringer Ingelheim Strengthen Collaboration with €5.5 Million Milestone Achievement in Retinal Disease Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2569078976","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569078976?lang=en_us&edition=fundamental","pubTime":"2025-09-22 19:30","pubTimestamp":1758540631,"startTime":"0","endTime":"0","summary":"Palatin Technologies and Boehringer Ingelheim Strengthen Collaboration with 5.5 Million Milestone Achievement in Retinal Disease Research. Palatin Technologies Inc. has achieved a significant milestone in its collaboration with Boehringer Ingelheim, earning a 5.5 million  payment. The partnership focuses on developing innovative melanocortin receptor-targeted treatments for retinal diseases, specifically aiming at conditions such as diabetic retinopathy and diabetic macular edema. This collaboration is part of a broader effort to create first-in-class treatments for these conditions, which impact a large number of individuals with diabetes. Carl Spana, Ph.D., President and CEO of Palatin, expressed enthusiasm for the progress made and the potential of melanocortin receptor agonists to address the core causes of these retinal diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timel","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nNDL6fZ3CL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTNT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PTNT\",params:#limit:6,delay:false,,,undefined,":[]}}